A single peptide study is easier to measure
[DOI] [PubMed] [Google Scholar] 44.Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P
Importantly, there were no cardiovascular adverse events, no clinically significant changes in blood pressure or heart rate, no alterations in thyroid function, no immunogenicity with no anti-AOD-9604 antibodies detected, and no signs of tolerance or receptor desensitization
References PubMed Clinical trial of Selank for generalized anxiety disorder (intranasal, human study) PubMed Selank for neurasthenia: 14-day clinical trial demonstrating anxiolytic and anti-asthenic effects (human study) Hindawi BioMed Research Intranasal Selank administration review: neurobehavioral effects and clinical applications (review article) Springer Primate studies: intranasal Selank eliminates anxiety behaviors with long-term effects (preclinical) Springer Selank attenuates opioid withdrawal symptoms in animal models (preclinical dosing study) CDC Vaccine administration best practices: subcutaneous injection technique and site selection Cleveland Clinic Subcutaneous injection guide: technique, sites, and rotation principles NCBI Bookshelf Clinical procedures: injection preparation, aseptic technique, and administration standards CDC Injection safety guidelines: single-use devices, sharps disposal, and preventing unsafe practices NIBSC Peptide storage guidelines: lyophilized and reconstituted stability considerations Research Resources SS-31 (10mg/30mg/50mg Vials) Dosage Protocol Quickstart Highlights SS31 (elamipretide) is a mitochondriatargeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane [1] , stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis [2]
